Antibody-drug conjugates in gastric cancer: from molecular landscape to clinical strategies.

IF 6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Gastric Cancer Pub Date : 2024-09-01 Epub Date: 2024-07-04 DOI:10.1007/s10120-024-01529-y

Jia-Lin Hao, Xin-Yun Li, Yu-Tong Liu, Ji-Xuan Lang, Di-Jie Liu, Chun-Dong Zhang

{"title":"Antibody-drug conjugates in gastric cancer: from molecular landscape to clinical strategies.","authors":"Jia-Lin Hao, Xin-Yun Li, Yu-Tong Liu, Ji-Xuan Lang, Di-Jie Liu, Chun-Dong Zhang","doi":"10.1007/s10120-024-01529-y","DOIUrl":null,"url":null,"abstract":"<p><p>Antibody-drug conjugates (ADCs) represent a crucial component of targeted therapies in gastric cancer, potentially altering traditional treatment paradigms. Many ADCs have entered rigorous clinical trials based on biological theories and preclinical experiments. Modality trials have also been conducted in combination with monoclonal antibody therapies, chemotherapies, immunotherapies, and other treatments to enhance the efficacy of drug coordination effects. However, ADCs exhibit limitations in treating gastric cancer, including resistance triggered by their structure or other factors. Ongoing intensive researches and preclinical experiments are yielding improvements, while enhancements in drug development processes and concomitant diagnostics during the therapeutic period actively boost ADC efficacy. The optimal treatment strategy for gastric cancer patients is continually evolving. This review summarizes the clinical progress of ADCs in treating gastric cancer, analyzes the mechanisms of ADC combination therapies, discusses resistance patterns, and offers a promising outlook for future applications in ADC drug development and companion diagnostics.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"887-906"},"PeriodicalIF":6.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastric Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10120-024-01529-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/4 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Antibody-drug conjugates (ADCs) represent a crucial component of targeted therapies in gastric cancer, potentially altering traditional treatment paradigms. Many ADCs have entered rigorous clinical trials based on biological theories and preclinical experiments. Modality trials have also been conducted in combination with monoclonal antibody therapies, chemotherapies, immunotherapies, and other treatments to enhance the efficacy of drug coordination effects. However, ADCs exhibit limitations in treating gastric cancer, including resistance triggered by their structure or other factors. Ongoing intensive researches and preclinical experiments are yielding improvements, while enhancements in drug development processes and concomitant diagnostics during the therapeutic period actively boost ADC efficacy. The optimal treatment strategy for gastric cancer patients is continually evolving. This review summarizes the clinical progress of ADCs in treating gastric cancer, analyzes the mechanisms of ADC combination therapies, discusses resistance patterns, and offers a promising outlook for future applications in ADC drug development and companion diagnostics.

Abstract Image

查看原文本刊更多论文

胃癌中的抗体-药物共轭物：从分子图谱到临床策略。

抗体药物共轭物（ADC）是胃癌靶向疗法的重要组成部分，有可能改变传统的治疗模式。基于生物学理论和临床前实验，许多 ADC 已进入严格的临床试验阶段。此外，还开展了与单克隆抗体疗法、化疗、免疫疗法和其他疗法联合使用的模式试验，以提高药物协调效应的疗效。然而，ADCs 在治疗胃癌方面表现出局限性，包括其结构或其他因素引发的耐药性。正在进行的深入研究和临床前实验正在取得进展，而药物开发流程和治疗期间的伴随诊断的改进也在积极提高 ADC 的疗效。胃癌患者的最佳治疗策略在不断发展。本综述总结了 ADC 治疗胃癌的临床进展，分析了 ADC 联合疗法的机制，探讨了耐药模式，并对 ADC 药物开发和伴随诊断的未来应用进行了展望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gastric Cancer 医学-胃肠肝病学

CiteScore

14.70

自引率

2.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Gastric Cancer is an esteemed global forum that focuses on various aspects of gastric cancer research, treatment, and biology worldwide. The journal promotes a diverse range of content, including original articles, case reports, short communications, and technical notes. It also welcomes Letters to the Editor discussing published articles or sharing viewpoints on gastric cancer topics. Review articles are predominantly sought after by the Editor, ensuring comprehensive coverage of the field. With a dedicated and knowledgeable editorial team, the journal is committed to providing exceptional support and ensuring high levels of author satisfaction. In fact, over 90% of published authors have expressed their intent to publish again in our esteemed journal.